Celularity (CELU)
NASDAQ:CELU
Top Page
Celularity
(NASDAQ:CELU)
Select Model
Select Model
Rating:44Neutral
Price Target:
$1.50
▲(20.00% Upside)
Action:UpgradedDate:01/13/26
The score is primarily weighed down by weak financial performance—large ongoing losses, declining revenue, and negative equity with meaningful debt. Technicals also point to a sustained downtrend with weak momentum. Valuation offers limited support given negative earnings and no dividend, while recent corporate events are mixed: liquidity improved via financing, but dilution/regulatory and shareholder constraints remain.
Positive Factors
Solid gross margin (~55%)
A sustained ~55% gross margin indicates the core therapeutic products have favorable unit economics. Over the medium term this supports scalable profitability if SG&A and R&D growth are controlled, and it strengthens the case for margin recovery as revenues stabilize.
Negative Factors
Deep unprofitability and falling revenue
Severe losses and shrinking revenue impair the company’s ability to self-fund growth and extend runway. Persistently negative margins force reliance on external capital, increasing dilution risk and constraining long-term investments in R&D and commercial scale-up.
Read all positive and negative factors
Positive Factors
Negative Factors
Solid gross margin (~55%)
A sustained ~55% gross margin indicates the core therapeutic products have favorable unit economics. Over the medium term this supports scalable profitability if SG&A and R&D growth are controlled, and it strengthens the case for margin recovery as revenues stabilize.
Read all positive factors
Celularity (CELU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$40.37M
Dividend YieldN/A
Average Volume (3M)206.82K
Price to Earnings (P/E)―
Beta (1Y)3.39
Revenue Growth-15.81%
EPS Growth-113.06%
CountryUS
Employees120
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding28,837,788
10 Day Avg. Volume277,262
30 Day Avg. Volume206,824
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)5.15
Price to Sales (P/S)0.84
P/FCF Ratio-6.94
Enterprise Value/Market Cap2.48
Enterprise Value/Revenue2.47
Enterprise Value/Gross Profit4.47
Enterprise Value/Ebitda-1.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.75
Revenue Forecast (FY)$44.00M
Celularity Business Overview & Revenue Model
Company Description
Celularity Inc. is a biotechnology company focused on developing innovative cell-based therapies for the treatment of cancer, degenerative diseases, and other serious conditions. The company leverages its proprietary platform that utilizes placent...
How the Company Makes Money
Celularity generates revenue through multiple streams, primarily from the commercialization of its cell therapies and related products. This includes sales of its therapeutic offerings directly to healthcare providers and hospitals. Additionally, ...
Celularity Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2025 | Dec 2023 | Dec 2022 | Mar 2022 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 40.58M | 54.22M | 22.77M | 17.98M | 21.34M | 14.28M |
| Gross Profit | 22.42M | 39.23M | 6.75M | -1.69M | 11.68M | 9.35M |
| EBITDA | -63.56M | -43.71M | -183.95M | -138.83M | -88.11M | -202.41M |
| Net Income | -80.64M | -57.89M | -196.29M | 14.19M | -100.12M | -208.23M |
Balance Sheet | ||||||
| Total Assets | 114.24M | 132.68M | 143.89M | 401.07M | 414.13M | 431.01M |
| Cash, Cash Equivalents and Short-Term Investments | 120.00K | 738.00K | 227.00K | 13.97M | 37.24M | 54.31M |
| Total Debt | 66.76M | 68.84M | 65.42M | 65.59M | 31.14M | 30.64M |
| Total Liabilities | 134.33M | 123.84M | 102.93M | 202.16M | 314.71M | 412.30M |
| Stockholders Equity | -20.09M | 8.84M | 40.96M | 198.90M | 99.42M | 18.71M |
Cash Flow | ||||||
| Free Cash Flow | -6.61M | -6.56M | -42.73M | -143.11M | -116.30M | -91.03M |
| Operating Cash Flow | -6.56M | -6.40M | -38.69M | -137.88M | -110.10M | -63.19M |
| Investing Cash Flow | -1.56M | 514.00K | -4.05M | -5.24M | -5.90M | -12.81M |
| Financing Cash Flow | 8.07M | 6.70M | 24.09M | 119.84M | 98.56M | 102.01M |
Celularity Technical Analysis
Positive
1.25
Price Trends
1.27
Positive
1.40
Negative
1.95
Negative
Market Momentum
0.02
Negative
61.83
Neutral
92.88
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELU, the sentiment is Positive. The current price of 1.25 is below the 20-day moving average (MA) of 1.27, below the 50-day MA of 1.27, and below the 200-day MA of 1.95, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 61.83 is Neutral, neither overbought nor oversold. The STOCH value of 92.88 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CELU.
Celularity Risk Analysis
Celularity disclosed 76 risk factors in its most recent earnings report. Celularity reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celularity Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $485.21M | -7.52 | -65.03% | ― | -84.46% | 33.32% | |
46 Neutral | $18.23M | ― | -1041.79% | ― | ― | 1.18% | |
44 Neutral | $40.37M | -0.59 | 763.31% | ― | -15.81% | -113.06% | |
40 Underperform | $4.81M | -0.54 | -1292.87% | ― | ― | 18.47% |
* Healthcare Sector Average
CELU
Celularity
1.40
0.01
0.72%
LTRN
Lantern Pharma
1.62
-1.19
-42.35%
STTK
Shattuck Labs
6.78
5.48
421.54%
FBLG
FibroBiologics, Inc.
1.37
-16.03
-92.13%
Celularity Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Celularity Secures New Financing To Support Strategic Shift
Positive
Dec 23, 2025
On December 19, 2025, Celularity Inc. entered into senior secured note and convertible note financings with investor Philip A. Barach, receiving $10 million in gross proceeds at closing and structuring commitments for up to an additional $2 millio...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Celularity Shareholders Reject Expansion of Equity Incentive Plan
Negative
Dec 19, 2025
Celularity Inc. held its Annual Meeting of Stockholders on December 19, 2025, where shareholders voted on director elections, auditor ratification and a proposed amendment to the company’s equity incentive plan. Stockholders reelected three ...
Legal ProceedingsRegulatory Filings and Compliance
Celularity Receives FDA Warning Over Marketing Claims
Negative
Dec 5, 2025
On December 1, 2025, Celularity Inc. received a warning letter from the FDA concerning the marketing materials for Interfyl, a human connective tissue matrix. The letter emphasized the need to limit outcome-based claims and metabolic activity desc...
Private Placements and Financing
Celularity Secures $2 Million in Private Placement
Neutral
Oct 28, 2025
On October 24, 2025, Celularity Inc. entered into a Securities Purchase Agreement with an institutional investor to issue and sell Series A Convertible Preferred Stock and accompanying warrants in a private placement transaction. The initial tranc...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.